Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Anavex Life Sciences Reported Preclinical Results In Directly To Humans' Translatable Biomarkers For Individuals With FXS For ANAVEX2-73 (Blarcamesine), In A Disease Model Of Fragile X Syndrome (FXS)

Author: Benzinga Newsdesk | July 30, 2024 07:41am

ANAVEX®2-73 corrects directly to humans' translatable EEG biomarkers in a model of Fragile X Syndrome (FXS).
Therapeutic potential to address behavioral and cognitive deficits in individuals with neurodevelopmental disorders
Plans advancing to initiate a clinical trial in individuals with FXS

Posted In: AVXL